Skip to main content

Autoinflammatory

Retro study 109 oligoarticular JIA pts (~8 yrs) Rx w/ intraarticular steroids w/ 4.3 yrs F/U: 38% needed no Rx, 15.5% needed more IAS; 46% systemic Rx(MTX; 8 mos) &22% biologics(2.2 yrs later). @FUV 89% were inactive. Persistence predicted by ANA+ & B27+ https://t.co/5YLkYyA84l https://t.co/wClhEiKOIw
Dr. John Cush @RheumNow( View Tweet )
HS-Related Autoinflammatory Syndromes HS is an autoinflammatory skin disorder of the terminal hair follicle, manifesting with painful nodules, abscesses, draining tunnels, and hypertrophic scarring, typically occurring in apocrine gland bearing skin. https://t.co/02Svwj99Bm https://t.co/9oy1UngII7
Dr. John Cush @RheumNow( View Tweet )

Hidradenitis Suppurativa-Related Autoinflammatory Syndromes

Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include 

Read Article
Effective Treatments for Still's Disease A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy of tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK). https://t.co/Qi98OXyoLJ https://t.co/DCgXfs0Bot
Dr. John Cush @RheumNow( View Tweet )

Effective Treatments for Still's Disease

A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy of tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK).



Data and results from 44 studies abstracts evaluated treatments, including nonsteroidal antiinflammatory drugs (

Read Article

Depression and RA (3.8.2024)

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week.

Read Article
Stills Dz Rx w/ IL-1 or IL-6 inhib may mask Dx of MAS! Study of 162 systemic JIA & MAS (62 on biologics). Biologic Rx pts had lower Plt, Ferritin (1107 vs 2863(, CRP (15 vs 90), ESR, fever duration. 27% on IL1/IL6i did not meetMAS classification criteria https://t.co/RmAzxh459R https://t.co/SXroqNBLSZ
Dr. John Cush @RheumNow( View Tweet )
Fever of Unknown Origin: Not Always an Infection Roel Sanchez Baez, MD presents his poster at RWCS 2024. https://t.co/WiDfcNHuNv https://t.co/gTs78QmE2A
Dr. John Cush @RheumNow( View Tweet )

Sniffles & Arthritis (3.1.2024)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are these associations with infection, biomarkers and weather real or imaginary? Linked or luck? Causal or casual?  You decide....





  1. No clear link between weather & MSK symptoms

Read Article

PAPA (pyogenic arthritis, pyoderma gangrenosum & acne) syndrome is a hereditary autoinflammatory Dz caused by dominant mutation in PSTPIP1 (triggers IFN-γ-mediated pyrin induction & IL-18 release; can be Tx by JAK inhibition) https://t.co/fy0MnwDA5U https://t.co/l8n2EwgV0t

Dr. John Cush @RheumNow( View Tweet )
Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases. https://t.co/r5WjYIdmaT https://t.co/gGdhyDKqtC
Dr. John Cush @RheumNow( View Tweet )
Transcriptome analysis (of PBMCs) looked for differential gene expression btwn 125 SJIA & 92 healthy controls identified 4 key genes (ALDH1A1, CEACAM1, YBX3 and SLC6A8) distinguishing SJIA; & may aid in diagnosis. https://t.co/M6pfajw3U3 https://t.co/VVwrYUJcBH
Dr. John Cush @RheumNow( View Tweet )
Systematic review of 44 studies looking at treatment of Stills Dz (AOSD), showing that tocilizumab, anakinra & canakinumab therapy are effective in AOSD. Complete remission: - TCZ 80% (57% Steroid D/C) - ANAK 73% (47% GC DC) - CAN 77% (34% GC DC) https://t.co/bFil81GGlJ https://t.co/F5NJ6m1gVF
Dr. John Cush @RheumNow( View Tweet )
JAMA Clinical Challenge - Recurrent Fever, Rash, and Shortness of Breath in a 69-Year-Old. Admited with fever, fatigue, rash, right periorbital swelling, SOB, Palpable purpural, Serositis previously - whats your diagnosis? https://t.co/j6aSGffpPv https://t.co/du6pEo74xp
Dr. John Cush @RheumNow( View Tweet )

New therapeutic approach for the treatment of sarcoidosis

Eureka Alert!

A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis. In a clinical study, the inhibition of a specific signaling pathway showed clear success in the treatment of granulomas in the skin. This

Read Article

What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review the challenges of these conditions. https://t.co/TXJbpD3yB4 https://t.co/QGDaZdqrqz

Dr. John Cush @RheumNow( View Tweet )
What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review the challenges of these conditions. https://t.co/3ssM9fMGCm https://t.co/FWZPx9Cpn7
Dr. John Cush @RheumNow( View Tweet )
AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/gvbPkeq2sH https://t.co/J25U6rWNTy
Dr. John Cush @RheumNow( View Tweet )
AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/vY1yZUX25S

Dr. John Cush @RheumNow( View Tweet )

StillsNow Podcast December 2023 - ACR23 Highlights

Dr. Jack Cush reviews selected AOSD & systemic JIA abstracts from the ACR 2023 Annual meeting held in San Diego, November 12th thru 16th.





  1. Abstract 0761. EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and

Read Article

AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/Hw9RECWYg5 https://t.co/A5JMCSpl0D

Dr. John Cush @RheumNow( View Tweet )

Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome

A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary

Read Article
Best of 2023: LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/5nzq6KvOpy https://t.co/Y2MCXkGck2
Dr. John Cush @RheumNow( View Tweet )

Best of 2023: LAVLI - A New Autoinflammatory Disorder

NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes

Read Article

DA Approves Canakinumab for Gout Flares The US FDA has approved canakinumab \ Ilaris\ for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. https://t.co/OX3wIajQtm https://t.co/tMDMc8ZKE8

Dr. John Cush @RheumNow( View Tweet )